Press releases

ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million

ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)

ORYZON to provide corporate progress updates at several events in November

ORYZON reports financial results and corporate updates for quarter ended September 30, 2023

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies

ORYZON to provide corporate progress updates at several events in October

ORYZON to give updates on corporate progress in September

Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder

ORYZON reports financial results and corporate updates for half-year ending June 30, 2023